JP2020504135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504135A5 JP2020504135A5 JP2019536859A JP2019536859A JP2020504135A5 JP 2020504135 A5 JP2020504135 A5 JP 2020504135A5 JP 2019536859 A JP2019536859 A JP 2019536859A JP 2019536859 A JP2019536859 A JP 2019536859A JP 2020504135 A5 JP2020504135 A5 JP 2020504135A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- hvr
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 178
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 20
- 210000004072 lung Anatomy 0.000 claims description 8
- 210000003979 eosinophil Anatomy 0.000 claims description 7
- 206010014561 Emphysema Diseases 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 210000000440 neutrophil Anatomy 0.000 claims description 6
- 208000030853 Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Diseases 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 4
- 238000001764 infiltration Methods 0.000 claims description 4
- 201000004193 respiratory failure Diseases 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000034309 Bacterial disease carrier Diseases 0.000 claims description 2
- 239000002028 Biomass Substances 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 230000007883 bronchodilation Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 230000005713 exacerbation Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000003434 inspiratory effect Effects 0.000 claims description 2
- 230000002427 irreversible effect Effects 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 43
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 40
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443591P | 2017-01-06 | 2017-01-06 | |
| US62/443,591 | 2017-01-06 | ||
| PCT/US2018/012694 WO2018129400A1 (en) | 2017-01-06 | 2018-01-05 | Methods and compositions for treating chronic obstructive pulmonary disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020504135A JP2020504135A (ja) | 2020-02-06 |
| JP2020504135A5 true JP2020504135A5 (cg-RX-API-DMAC7.html) | 2021-02-12 |
Family
ID=62790958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536859A Pending JP2020504135A (ja) | 2017-01-06 | 2018-01-05 | 慢性閉塞性肺障害を処置するための方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190338027A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3565597A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020504135A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018129400A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015222757B2 (en) | 2014-02-28 | 2020-10-08 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
| CA2987797A1 (en) | 2015-06-17 | 2016-12-22 | Christopher Robert Bebbington | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| CN110831628A (zh) | 2017-05-05 | 2020-02-21 | 爱乐科斯公司 | 用于治疗过敏性眼病的方法和组合物 |
| US20220257758A1 (en) * | 2019-08-02 | 2022-08-18 | Allakos Inc. | Methods of administering anti-siglec-8 antibodies and corticosteroids |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001066126A1 (en) * | 2000-03-07 | 2001-09-13 | Smithkline Beecham Corporation | Sialoadhesin factor-2 antibodies |
| ES2758508T3 (es) * | 2013-12-09 | 2020-05-05 | Allakos Inc | Anticuerpos dirigidos contra Siglec-8 y métodos de uso de los mismos |
| AU2015222757B2 (en) * | 2014-02-28 | 2020-10-08 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
| CA2987797A1 (en) * | 2015-06-17 | 2016-12-22 | Christopher Robert Bebbington | Methods and compositions for treating fibrotic diseases |
-
2018
- 2018-01-05 JP JP2019536859A patent/JP2020504135A/ja active Pending
- 2018-01-05 US US16/476,027 patent/US20190338027A1/en not_active Abandoned
- 2018-01-05 WO PCT/US2018/012694 patent/WO2018129400A1/en not_active Ceased
- 2018-01-05 EP EP18736183.7A patent/EP3565597A4/en not_active Withdrawn